REQUEST A DEMO
Total
USD $0.00
Search more companies

Nh Special Purpose Acquisition 17 Company (South Korea)

Main Activities: All Other Financial Investment Activities | Other Professional, Scientific, and Technical Services
Full name: Nh Special Purpose Acquisition 17 Company Profile Updated: February 22, 2024
Buy our report for this company USD 29.95 Most recent financial data: 2022 Available in: English Download a sample report

The Company is a Korea-based company is mainly engaged in the clinical trial agency and drug development business. The Company is mainly engaged in the provision of comprehensive early-stage clinical services in the areas of medical writing, regulatory matters, data management, biostatistics and others. The Company is mainly engaged in the provision of consulting services including initial clinical development, clinical trial development, global clinical trial development and others. In addition, the Company is also engaged in the operation of clinical trial training center. The Company was established on June 18, 2020. The Company share was listed on the Korea Securities Dealers Automated Quotation System ( KOSDAQ ) on September 23, 2020.

Headquarters
C R Bldg., 412, Yeoksam-Ro, Gangnam-Gu
Seoul; Seoul;

Contact Details: Purchase the Nh Special Purpose Acquisition 17 Company report to view the information.

Basic Information
Total Employees:
Purchase the Nh Special Purpose Acquisition 17 Company report to view the information.
Outstanding Shares:
Purchase the Nh Special Purpose Acquisition 17 Company report to view the information.
Registered Capital:
Purchase the Nh Special Purpose Acquisition 17 Company report to view the information.
Financial Auditors:
Purchase the Nh Special Purpose Acquisition 17 Company report to view the information.
Incorporation Date:
June 18, 2020
Key Executives
Purchase this report to view the information.
CEO
Purchase this report to view the information.
Non-Executive Independent Director
Purchase this report to view the information.
Non-Executive Independent Director
Purchase this report to view the information.
Auditor
Purchase this report to view the information.
Vice President
Subsidiaries
C R Healthcare Global (Singapore)
C R Research China (China)
Company Performance
Financial values in the chart are available after Nh Special Purpose Acquisition 17 Company report is purchased.
Looking for more than just a company report?

EMIS company profiles are part of a larger information service which combines company, industry and country data and analysis for over 145 emerging markets.

Request a demo of the EMIS service
Key Financial Highlights
Annual growth percentages for latest two years in local currency KRW. Absolute financial data is included in the purchased report.
Net sales revenue
8.51%
Total operating revenue
8.17%
Operating profit (EBIT)
-5.12%
EBITDA
6.3%
Net Profit (Loss) for the Period
0.28%
Total assets
-5.39%
Total equity
13.05%
Operating Profit Margin (ROS)
-1.14%
Net Profit Margin
-0.61%
Return on Equity (ROE)
-0.94%
Debt to Equity Ratio
-13.87%
Quick Ratio
0.08%
Cash Ratio
-0.16%

To view more information, Request a demonstration of the EMIS service

Buy this company report
Need ongoing access to company, industry or country information?